{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-071928","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.451964+00:00","generated_at":"2026-05-17T22:50:49.771775+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"confidence":"high","headline":"Madrigal in-licenses oral GLP-1 SYH2086 from CSPC for up to $2B in milestones","bullets":["Upfront payment of $120M; potential milestone payments up to $2B plus royalties on net sales.","Madrigal plans to start clinical development for SYH2086 in first half of 2026; deal expected to close Q4 2025.","Aims to combine Rezdiffra (resmetirom) with oral GLP-1 for MASH, citing enhanced antifibrotic benefit with modest weight loss.","CSPC retains rights to develop other oral GLP-1 agonists in China subject to conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-071928","json":"https://secwatch.observer/filing/0001104659-25-071928.json","markdown":"https://secwatch.observer/filing/0001104659-25-071928.md","text":"https://secwatch.observer/filing/0001104659-25-071928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000110465925071928/0001104659-25-071928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000110465925071928/tm2522007d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:50:49.771775+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}